Journal article
Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
Drug and alcohol dependence, Vol.85(3), pp.177-184
2006
Handle:
https://hdl.handle.net/2376/108904
PMID: 16740370
Abstract
To conduct a 16-week, randomized, placebo-controlled, double-blind trial of two GABAergic medications, baclofen (20
mg tid) and gabapentin (800
mg tid), for the treatment of methamphetamine dependence.
Adults with methamphetamine dependence were randomized to one of three conditions for 16 weeks: baclofen (
n
=
25), gabapentin (
n
=
26) or placebo (
n
=
37). All participants attended clinic thrice weekly to receive study medication and psychosocial counseling, complete study assessments, and provide urine samples.
No statistically significant main effects for baclofen or gabapentin in reducing methamphetamine use were observed using a generalized estimating equation (GEE). A significant treatment effect was found in post hoc analyses for baclofen, but not gabapentin, relative to placebo among participants who reported taking a higher percentage of study medication (significant treatment group and medication adherence interaction in GEE model of methamphetamine use).
While gabapentin does not appear to be effective in treating methamphetamine dependence, baclofen may have a small treatment effect relative to placebo. Future studies evaluating the effectiveness of baclofen and other GABAergic agents for treatment of methamphetamine may be warranted.
Metrics
7 Record Views
Details
- Title
- Randomized, placebo-controlled trial of baclofen and gabapentin for the treatment of methamphetamine dependence
- Creators
- Keith G Heinzerling - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USASteven Shoptaw - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USAJames A Peck - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USAXiaowei Yang - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USAJuanmei Liu - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USAJohn Roll - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USAWalter Ling - Integrated Substance Abuse Programs, Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine at UCLA, Los Angeles, CA 90024, USA
- Publication Details
- Drug and alcohol dependence, Vol.85(3), pp.177-184
- Academic Unit
- Elson S. Floyd College of Medicine
- Publisher
- Elsevier Ireland Ltd
- Identifiers
- 99900546970401842
- Language
- English
- Resource Type
- Journal article